Neogenomics Inc. (NEO) concluded trading on Wednesday at a closing price of $16.48, with 4.09 million shares of worth about $67.41 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.05% during that period and on Wednesday the price saw a gain of about 12.11%. Currently the company’s common shares owned by public are about 127.37M shares, out of which, 125.93M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 10 times over the past 12 months. They bought 1,507 shares in 1 of the transactions. In 9 selling transactions, insiders dumped 31,187 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 16.50, or with a gain of 12.11%. Stock saw a price change of 15.24% in past 5 days and over the past one month there was a price change of 3.00%. Year-to-date (YTD), NEO shares are showing a performance of 1.85% which increased to 18.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.03 but also hit the highest price of $21.22 during that period. The average intraday trading volume for Neogenomics Inc. shares is 1.04 million. The stock is currently trading 10.08% above its 20-day simple moving average (SMA20), while that difference is down -0.27% for SMA50 and it goes to 3.78% higher than SMA200.
Neogenomics Inc. (NASDAQ: NEO) currently have 127.37M outstanding shares and institutions hold larger chunk of about 99.36% of that.
The stock has a current market capitalization of $2.10B and its 3Y-monthly beta is at 1.10. It has posted earnings per share of -$0.70 in the same period. It has Quick Ratio of 5.95 while making debt-to-equity ratio of 0.65. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NEO, volatility over the week remained 5.44% while standing at 4.64% over the month.
Analysts are in expectations that Neogenomics Inc. (NEO) stock would likely to be making an EPS of -$0.05 in the current quarter, while forecast for next quarter EPS is -$0.03 and it is $0.09 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.2 which is -$0.01 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.09 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 89.86% while it is estimated to increase by 1189.83% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on December 29, 2023 offering a Buy rating for the stock and assigned a target price range of between $25 and $21 to it. Coverage by Stephens stated Neogenomics Inc. (NEO) stock as an Overweight in their note to investors on August 21, 2023, suggesting a price target of $18 for the stock. On May 16, 2023, Raymond James Downgrade their recommendations, while on May 09, 2023, BTIG Research Upgrade their ratings for the stock with a price target of $25. Stock get a Buy rating from The Benchmark Company on February 24, 2023.
